Peritoneal (Abdominal Mesothelioma)
The role of cytoreductive surgery and HIPEC for the treatment of primary and secondary peritoneal malignancies-experience from a tertiary care center in Germany
Langenbeck’s Archives of Surgery 2024 April 8 [Link] Mikko Reese, Ann-Kathrin Eichelmann, Tobias M Nowacki , Andreas Pascher, Judith C Sporn Abstract Purpose: Peritoneal surface malignancies (PSM) are commonly known to have a dismal prognosis. Over the past decades, novel techniques such as cytoreductive surgery (CRS), hyperthermic intraperitoneal chemotherapy (HIPEC), and pressurized intraperitoneal aerosol chemotherapy…
Read MoreGuidelines for Pathologic Diagnosis of Mesothelioma
Archives of Pathology and Laboratory Medicine 2024 April 8 [Link] Aliya N Husain, David B Chapel, Richard Attanoos, Mary Beth Beasley, Luka Brcic, Kelly Butnor, Lucian R Chirieac, Andrew Churg, Sanja Dacic, Francoise Galateau-Salle, Kenzo Hiroshima, Yin P Hung, Sonja Klebe, Thomas Krausz, Andras Khoor, Leslie Litzky, Alberto Marchevsky, Kazuki Nabeshima, Andrew G Nicholson, Elizabeth…
Read MoreImplementation of a high-resolution, high-contrast magnetic resonance imaging protocol with extended delayed phases for peritoneal mesothelioma
Quantitative Imaging in Medicine and Surgery 2024 March 15 [Link] Milica Medved, Hunter D D Witmer, Ankit Dhiman, Yaniv Berger, Scott K Sherman, Enal S Hindi, Samuel G Armato 3rd, Ingrid S Reiser, Aytekin Oto, Roger M Engelmann, Hedy L Kindler, Nisa C Oren, Carla B Harmath, Kiran K Turaga Abstract Background: Imaging of peritoneal…
Read MorePeritoneal Malignant Mesothelioma Metastasizing to Lymph Node in Young Male-a Case Report
Indian Journal of Surgical Oncology 2024 March [Link] Amanpreet Singh, Cherry Bansal, Disha Singla, Sarika More, Shivani Chabhra, Shazia Bashir Abstract Peritoneal malignant mesothelioma is an uncommon neoplasm with a poor prognosis. We hereby report a case of a 20-year-old male, first diagnosed on biopsy with axillary lymph node metastasis. He presented with abdominal pain…
Read MoreVenous Thromboembolism in Peritoneal Mesothelioma: Uncovering the Hidden Risk
Annals of Surgical Oncology 2024 February 19 [Link] Varun V Bansal, Owen Mitchell, Celyn Bregio, Hunter D D Witmer, Ankit Dhiman, Frederick A Godley 4th, Cecilia Ong, Yaniv Berger, Biren Reddy, Jane E Churpek, Michael W Drazer, Oliver S Eng, Hedy L Kindler, Kiran K Turaga Abstract Introduction: Venous thromboembolism (VTE) is a common complication…
Read MoreIs extereme cytoreductive surgery beneficial to survival ın malignant peritoneal mesothelioma?
Acta Chirurgica Belgica 2024 February 14 [Link] Murat Can Mollaoğlu, Ufuk Karabacak, Meriç Emre Bostancı, Turan Eray Seven, Kürşat Karadayı Abstract Introduction: Malign peritoneal mesothelioma (MPM) is an uncommon disease that is difficult to treat. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) are the gold standards for treating MPM. Sometimes extreme cytoreductive surgery (eCRS) is…
Read MoreClinical and pathological observation of conversion therapy for malignant peritoneal mesothelioma: a case report and literature review
Pathology Oncology Research 2024 January 8 [Link] Minying Deng, Xinyi Zhang, Chen Xu, Rongkui Luo, Lingli Chen, Yuhong Zhou, Yingyong Hou Abstract Background: Malignant mesothelioma (MM) is a tumor originating from the pleura, peritoneum, or pericardial cavity. It is divided into diffuse and localized malignant mesothelioma, with four subtypes in diffuse MM: epithelioid, sarcomatoid, desmoplastic,…
Read MoreReflecting real-world patients with mesothelioma in research: an interim report of baseline characteristics from the ASSESS-meso cohort
ERJ Open Research 2023 December 27 [Link] Ruairi J H Conway, Natalie Smith, William Cooper, Geraldine Lynch, Sonia Patole, Jenny Symonds, Anthony Edey, Nick A Maskell, Anna C Bibby Abstract Objective: Mesothelioma varies in clinical phenotype and survival. Clinical trials are unavoidably affected by selection bias, reducing generalisability. ASSESS-meso is a UK, multicentre, prospective, mesothelioma…
Read MoreMethylthioadenosine Phosphorylase and Breast Cancer 1 Protein-Associated Protein 1 as Biomarkers for the Peritoneal Mesothelioma
Cancer Control 2023 January-December [Link] Yue Chen, Xuemei Du, Ying Gao, Heliang Wu, Hongyu Zhao, Yandong Su Abstract Objectives: Combination of Breast Cancer 1 protein-associated protein 1 (BAP1) and methylthioadenosine phosphorylase (MTAP) in the peritoneal mesothelioma (PeM) has yet to be explored. We aim to assess the diagnostic value of combined BAP1 and MTAP to…
Read MoreAnalysis of Ki67 Protein Expression and Clinicopathological Features in Patients with Peritoneal Mesothelioma
Alternative Therapies in Health and Medicine 2023 December 8 [Link] Dujuan Yang, Yeping Zhou, Kongdan Lv Abstract Background: At present, there are many treatments for peritoneal mesothelioma, but the treatment of peritoneal mesothelioma is still facing great challenges. Distant metastasis is the main cause of poor prognosis and death of patients with peritoneal mesothelioma. Ki67…
Read More